Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance

Repligen Corp (RGEN) reported Q3 2026 revenue of $209M, up 12.5% organically, and raised 2026 guidance. Chromatography and proteins grew over 40%, while filtration declined 11%. BioLife acquisition is expected to be $0.05 accretive in 2027. Capital equipment orders increased mid-teens YoY, but revenue lags due to slow customer decisions. Inflationary pressures and product mix headwinds impacted margins. The company recorded a $41M intangible asset impairment.

Original reporting
Published Oct 27, 2026, 7:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 7:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance — source image
Decision brief

The 30-second read

$RGENNeutralHigh
01

Why it matters

The guidance raise is likely to attract buying interest, but operational headwinds could limit the rally.

02

Market read

First disclosure of new guidance makes this a primary earnings news piece with immediate trading relevance.

03

What to watch

Integration risk of BioLife and delayed onshoring orders may dampen long‑term upside.

Relevance 7/10Novelty 8/10Timing: after-hours earnings release

Background

Repligen's Q3 earnings call disclosed record revenue, organic growth, and updated 2026 guidance after acquiring BioLife.

Company-level read

Ticker impact

$RGENNeutralMedium confidence
Context

Repligen reported record Q3 revenue and raised 2026 guidance to $2.05-$2.09 EPS, adding material new guidance.

Expected impact

potential modest upside as investors price in higher EPS guidance, offset by concerns over filtration decline

Evidence & confidence

Guidance lift is a fresh, material fact; however mixed operating metrics create uncertainty.

Market effects

Biotech tools sector may see broader optimism from Repligen's guidance lift.

US biotech stocks could experience slight rally in early trading.

Limited to investors tracking US-listed life‑science equipment companies.

Counterpoint

Filtration revenue miss and margin compression could lead to a short‑term pullback despite guidance raise.

Key entities

  • Repligen Corp

    US‑listed biotech tools manufacturer (NASDAQ:RGEN).

  • BioLife

    Recent acquisition expected to be accretive in 2027.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.